Seeking Alpha

MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
View MissionIR's Instablogs on:
  • Osage Exploration And Development, Inc. (OEDV) Expanded Nemaha Ridge Project In Oklahoma Spuds Third Horizontal Mississippian Well

    Osage Exploration and Development has assembled a sizeable acreage footprint in domestic hydrocarbons, with an emphasis on working Horizontal Mississippian vectors in Oklahoma (in addition to the company's majority interest in the Guaduas field in Colombia), releasing news today about their latest E&P achievement, the spudding of a third horizontal well (Davis Farms 2-5H) on the company's 28k-acre Nemaha Ridge project in Logan County, Oklahoma.

    Two miles south of OEDV's Wolf 1-29H well, the Davis Farms 2-5H (which follows fast on the heels of the drilling of its disposal well, the Davis Farms 1-5 SWD) hopes to produce initial production rates similar to the Wolf 1-29H (1,185 barrels per day in initial 72-hour period, with an 84% forty degree gravity crude oil and 16% high BTU wet gas, Wolf 1-29H is one of the best targets executed in the play thus far).

    Nemaha Ridge is being developed in conjunction with OEDV's operational partners, both of whom have extensive Oklahoma presence and decades in the industry, Slawson Exploration Company and US Energy Development Corporation (USEDC). The widely acclaimed Slawson has been at this sort of work for over five decades and has a regional office in Oklahoma to support activities (over 3,500 wells drilled in 10 states, with some of the first horizontals under its belt from back in the 80's). USEDC grew out of Oilmark & Company, Inc., founded back in 1978, and is today regarded as one of the top 50 independent domestic hydrocarbon drillers with extensive work in both NY and Pennsylvania (operator status on over 2,500 well drillings since inception).

    The Nemaha Ridge project is brilliantly engineered and the execution has just been superb. Osage has some of the best operational logistics available and is flexing this muscle with an aggressive attitude towards acquisitions in Oklahoma, as well as onshore U.S. targets in general.

    Chairman and CEO of OEDV, Kim Bradford, underscored the recently announced 40% expansion of the acreage position across the Mississippian, with OEDV's own position via the 25% working interest rising to as much as 7k net acres. Bradford deliberately showed his hand here, making it very clear that OEDV is intent on seizing a large horizontally-viable position in the play, confident that a strategy of moving to drill every single acre under lease will provide the greatest shareholder value accumulation.

    Bradford further emphasized OEDV's proven ability to simultaneously bring in impressive production results and expand the acreage footprint in the core operating area, citing that the company was no longer alone regionally, as three of the largest public E&P companies operating in the state have recently set up shop in Logan County as well (even drilling on contiguous acreage).

    Director and VP of Exploration at OEDV, Greg Franklin, echoed his colleagues' statements wholeheartedly, adding his own observation that the economic viability of the Horizontal Mississippian is now a widely-known fact among the industry's top analysts. Franklin pointed to volatile commodity prices as making the superior well economics (as expressed by OEDV's portfolio) especially attractive.

    Franklin cited extant E&P efforts as proof in-and-of-itself that OEDV can execute on this methodology and bring oil to the surface cheaply, yet with a maximum respect for the land and water table. So far, expectations have not only been met in this regard, but exceeded, with the theoretical work being done by OEDV realized through optimal production solutions and the latest in horizontal technology.

    OEDV has proven a capacity for elegantly partnering its way into more and more stable configurations, with the Guaduas Field and Guaduas-La Dorada Pipeline projects down in Colombia offering a solid test group, the health of OEDV's strategy seems clear and the future certain.

    For more information on San Diego-based, Osage Exploration and Development, Inc. (production offices in OKC and also down in Bogota), please visit the company's website at:

    Please see disclaimer on the MissionIR website

    Tags: OEDV
    Jun 04 1:53 PM | Link | Comment!
  • Marshall Edwards, Inc. (MSHL) Reveals Clinical Trial Results For Oncology Drug

    Marshall Edwards is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The company's lead drug candidates, ME-143 and ME-344, have shown in laboratory studies to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism.

    The company reported results from a Phase I clinical trial of its ME-143 drug candidate in patients with solid refractory tumors. Marshall Edwards stated that "ME-143 appears to be generally well tolerated with minimal toxicity …in heavily treated patients." The trial began in September 2011 after FDA approval of an Investigational New Drug (NYSE:IND) application. A total of 15 patients with solid tumors were enrolled in escalating weekly dose cohorts of 2.5mg/kg, 5mg/kg, 10mg/kg and 20mg/kg.

    The median number of prior therapies was four. Stable disease was observed in one patient at more than 15 weeks. This result is comparable to Phase I studies of Phenooxodiol, the company's first generation NADH oxidase inhibitor, in which stable disease was also the best response observed during the study. The study was a success in that it achieved the main objective of establishing a recommended dose for the next phase of development and also set the maximum dosage at 20mg/kg.

    Marshall Edwards is now looking forward to further studies of ME-143 in combination with cytotoxic therapies. The company is preparing for the first of its Phase II efficacy studies of the drug in combination with standard-of-care chemotherapy later this year.

    For additional information about Marshall Edwards and its oncology drug candidates, please visit the company's website at

    Please see disclaimer on the MissionIR website

    Tags: MEIP
    Jun 04 1:52 PM | Link | Comment!
  • FluoroPharma Medical, Inc. (FPMI): A Key Player Against Heart Disease

    FluoroPharma, a developer of advanced tracing chemicals used with positron emission tomography (PET) to help detect heart disease and other problems, recently received a positive report from Life Tech Capital Institutional Research. The points emphasized on top of the report tell much of the story:

    • Three "Shots-on-Goal" in Cardiac PET Imaging
    • Cardiac Disease is #1 Killer in U.S. and the World
    • Growing M&A Interest in Molecular Imaging Space

    The report went on to detail how FluoroPharma is in a good position to meet growing critical needs in healthcare, including their financial position. The primary focus of the report was on FluoroPharma's work with PET tracer chemicals for identifying heart disease, although the company is also now investigating tracers for the early identification of Alzheimer's disease.

    Cardiac disease is the world's leading killer, according to the World Health Organization, taking the lives of millions every year, with the exact number varying depending upon what is included in the definition. In developed countries, like the U.S., it takes the highest percentage of lives, with almost a third of all deaths attributable to it.

    Although there are continued efforts to address smoking, diet, and exercise, one of the biggest factors in countering the disease is early detection, which is where FluoroPharma comes in. The company's proprietary chemicals allow PET scanners to immediately spot areas of biological activity, at the cellular or even molecular level, that suggest developing cardiovascular disease, long before any symptoms appear. Their tracer chemicals (the "Three Shots on Goal"), BFPET, CardioPET, and VasoPET, are non-invasive imaging agents, allowing doctors and researchers to see the human body, and the heart process, as never before. Early detection will not only save lives, but huge amounts of money in the treatment of heart disease.

    For more information, see the company website at

    Please see disclaimer on the MissionIR website

    Jun 01 5:43 PM | Link | Comment!
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.